PT4051688T - Inibidores de cd73 - Google Patents

Inibidores de cd73

Info

Publication number
PT4051688T
PT4051688T PT208832881T PT20883288T PT4051688T PT 4051688 T PT4051688 T PT 4051688T PT 208832881 T PT208832881 T PT 208832881T PT 20883288 T PT20883288 T PT 20883288T PT 4051688 T PT4051688 T PT 4051688T
Authority
PT
Portugal
Prior art keywords
inhibitors
Prior art date
Application number
PT208832881T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Oric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oric Pharmaceuticals Inc filed Critical Oric Pharmaceuticals Inc
Publication of PT4051688T publication Critical patent/PT4051688T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT208832881T 2019-10-30 2020-10-29 Inibidores de cd73 PT4051688T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962928138P 2019-10-30 2019-10-30
US202062987806P 2020-03-10 2020-03-10
US202063088646P 2020-10-07 2020-10-07

Publications (1)

Publication Number Publication Date
PT4051688T true PT4051688T (pt) 2025-06-30

Family

ID=75686256

Family Applications (1)

Application Number Title Priority Date Filing Date
PT208832881T PT4051688T (pt) 2019-10-30 2020-10-29 Inibidores de cd73

Country Status (19)

Country Link
US (7) US12577272B2 (cg-RX-API-DMAC7.html)
EP (2) EP4051688B1 (cg-RX-API-DMAC7.html)
JP (2) JP7544815B2 (cg-RX-API-DMAC7.html)
KR (2) KR102727229B1 (cg-RX-API-DMAC7.html)
CN (2) CN116854758A (cg-RX-API-DMAC7.html)
AU (1) AU2020375914B2 (cg-RX-API-DMAC7.html)
CA (1) CA3159248C (cg-RX-API-DMAC7.html)
DK (1) DK4051688T3 (cg-RX-API-DMAC7.html)
ES (1) ES3034168T3 (cg-RX-API-DMAC7.html)
FI (1) FI4051688T3 (cg-RX-API-DMAC7.html)
HU (1) HUE072504T2 (cg-RX-API-DMAC7.html)
IL (2) IL292570B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022005256A (cg-RX-API-DMAC7.html)
PL (1) PL4051688T3 (cg-RX-API-DMAC7.html)
PT (1) PT4051688T (cg-RX-API-DMAC7.html)
SI (1) SI4051688T1 (cg-RX-API-DMAC7.html)
TW (1) TWI830962B (cg-RX-API-DMAC7.html)
WO (1) WO2021087136A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202204941B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CA3098493A1 (en) 2018-04-30 2019-11-07 Oric Pharmaceuticals, Inc. Cd73 inhibitors
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN116854758A (zh) 2019-10-30 2023-10-10 欧瑞克制药公司 Cd73抑制剂
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
CA3266927A1 (en) * 2022-09-14 2024-03-21 Oric Pharmaceuticals, Inc. PHARMACEUTICAL FORMS OF A CD73 INHIBITOR
US20240140980A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
US20240140979A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
WO2025111247A1 (en) * 2023-11-20 2025-05-30 Oric Pharmaceuticals, Inc. Treatment of refractory multiple myeloma
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1023991A (en) 1911-07-29 1912-04-23 Firm B Byers Anti-rail-creeper and splice-bar.
EP0477454A1 (en) 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
JP2005502580A (ja) 2000-12-15 2005-01-27 フアーマセツト・リミテツド フラビウィルス感染治療用抗ウィルス薬
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US20090274686A1 (en) 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
EP3134411B1 (en) * 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
US10383929B2 (en) * 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
LT3399984T (lt) * 2016-01-08 2023-11-10 Arcus Biosciences, Inc. 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas
CN110234656B (zh) 2016-09-09 2023-02-28 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
WO2018067424A1 (en) * 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
CN110022881B (zh) 2016-11-18 2023-05-02 艾库斯生物科学有限公司 Cd73介导的免疫抑制的抑制剂
KR102638592B1 (ko) 2016-12-22 2024-02-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 억제제 및 이의 용도
WO2018183635A1 (en) * 2017-03-31 2018-10-04 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
WO2018208727A1 (en) * 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN111094317B (zh) 2017-12-29 2023-03-31 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
CA3098493A1 (en) 2018-04-30 2019-11-07 Oric Pharmaceuticals, Inc. Cd73 inhibitors
TW202017569A (zh) 2018-05-31 2020-05-16 美商佩樂敦治療公司 用於抑制cd73之組合物及方法
KR102902754B1 (ko) 2018-06-21 2025-12-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 저해제 및 이의 사용 방법
ES3053198T3 (en) 2018-08-27 2026-01-20 Arcus Biosciences Inc Cd73 inhibitors
CA3143496A1 (en) 2019-06-20 2020-12-24 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN116854758A (zh) 2019-10-30 2023-10-10 欧瑞克制药公司 Cd73抑制剂

Also Published As

Publication number Publication date
CN114929721B (zh) 2023-07-18
IL292570B1 (en) 2023-12-01
US11530236B2 (en) 2022-12-20
IL308293B2 (en) 2025-12-01
EP4596048A3 (en) 2025-11-19
ES3034168T3 (en) 2025-08-13
JP7688769B2 (ja) 2025-06-04
CN114929721A (zh) 2022-08-19
JP2024164093A (ja) 2024-11-26
IL292570A (en) 2022-06-01
JP2023500483A (ja) 2023-01-06
US20210214387A1 (en) 2021-07-15
US12454544B2 (en) 2025-10-28
AU2020375914B2 (en) 2024-05-23
TW202130353A (zh) 2021-08-16
FI4051688T3 (fi) 2025-06-27
EP4051688A4 (en) 2024-03-06
EP4051688B1 (en) 2025-04-23
US20250034198A1 (en) 2025-01-30
PL4051688T3 (pl) 2025-09-22
JP7544815B2 (ja) 2024-09-03
EP4596048A2 (en) 2025-08-06
HUE072504T2 (hu) 2025-11-28
US11028120B2 (en) 2021-06-08
CA3159248C (en) 2024-05-28
KR20220088786A (ko) 2022-06-28
US20230131747A1 (en) 2023-04-27
US20210130390A1 (en) 2021-05-06
WO2021087136A1 (en) 2021-05-06
TWI830962B (zh) 2024-02-01
IL308293A (en) 2024-01-01
IL308293B1 (en) 2025-08-01
US12577272B2 (en) 2026-03-17
US20260042794A1 (en) 2026-02-12
US20220411459A1 (en) 2022-12-29
AU2020375914A1 (en) 2022-06-02
US20210130389A1 (en) 2021-05-06
BR112022008365A2 (pt) 2023-03-28
IL292570B2 (en) 2024-04-01
SI4051688T1 (sl) 2025-08-29
MX2022005256A (es) 2022-08-25
CA3159248A1 (en) 2021-05-06
EP4051688A1 (en) 2022-09-07
ZA202204941B (en) 2024-10-30
US11130778B2 (en) 2021-09-28
US12018043B2 (en) 2024-06-25
KR102727229B1 (ko) 2024-11-06
KR102653726B1 (ko) 2024-04-01
BR122023021184A2 (pt) 2024-02-27
NZ788133A (en) 2024-03-22
DK4051688T3 (da) 2025-06-30
KR20240042573A (ko) 2024-04-02
CN116854758A (zh) 2023-10-10

Similar Documents

Publication Publication Date Title
IL277006A (en) CD73 inhibitors
IL304348A (en) cd73 inhibitors
HUE072504T2 (hu) CD73-inhibitorok
SG11202106520VA (en) Kif18a inhibitors
GB201905265D0 (en) Inflammasome inhibition
EP3999517A4 (en) CD73 INHIBITORS
EP3956341A4 (en) CD73 INHIBITORS
GB201914860D0 (en) Inhibitor compounds
IL292093A (en) Thianopyrimidones as trpa1 inhibitors
IL290087A (en) inhibitory substances
IL276013A (en) pi4kiiibeta inhibitors
GB201819126D0 (en) Inhibitor compounds
SG11202102379XA (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
IL292095A (en) Thianopyrimidones as trpa1 inhibitors
GB201905328D0 (en) Inhibitor compounds
GB201819136D0 (en) Inhibitor compounds
HK40057128A (en) Cd73 inhibitors
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors
GB201905318D0 (en) Inhibitor compounds
GB201916329D0 (en) Disclosure
IL269414A (en) Rapar for safetyin taneis
GB201905370D0 (en) Elastate inhibition
GB201903609D0 (en) Disclosure
GB201812462D0 (en) Inhibitors